Literature DB >> 17943332

Decision-analytical modelling in health-care economic evaluations.

Xin Sun1, Thomas Faunce.   

Abstract

OBJECTIVE: Decision-analytical modelling is widely used in health-care economic evaluations, especially in situations where evaluators lack clinical trial data, and in circumstances where such evaluations factor into reimbursement pricing decisions. This paper aims to improve the understanding and use of modelling techniques in this context, with particular emphasis on Markov modelling.
METHODS: We provide an overview, in this paper, of the principles and methodological details of decision-analytical modelling. We propose a common route for practicing modelling that accommodates any type of decision-analytical modelling techniques. We use the treatment of chronic hepatitis B as an example to indicate the process of development, presentation and analysis of the Markov model, and discuss the strengths, weaknesses and pitfalls of different approaches.
CONCLUSIONS: Good practice of modelling requires careful planning, conduct and analysis of the model, and needs input from modellers and users.

Entities:  

Mesh:

Year:  2007        PMID: 17943332     DOI: 10.1007/s10198-007-0078-x

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  22 in total

1.  Population- versus cohort-based modelling approaches.

Authors:  Olivier Ethgen; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

Review 2.  [Modeling in value-based medicine].

Authors:  A S Neubauer; C Hirneiss; A Kampik
Journal:  Ophthalmologe       Date:  2010-03       Impact factor: 1.059

3.  Understanding and Identifying Key Issues with the Involvement of Clinicians in the Development of Decision-Analytic Model Structures: A Qualitative Study.

Authors:  Samantha Husbands; Susan Jowett; Pelham Barton; Joanna Coast
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

4.  Cost-effectiveness analysis of two therapeutic schemes in the treatment of acromegaly: a retrospective study of 168 cases.

Authors:  L Duan; M Huang; H Yan; Y Zhang; F Gu
Journal:  J Endocrinol Invest       Date:  2015-03-18       Impact factor: 4.256

5.  An analysis of the influence of framework aspects on the study design of health economic modeling evaluations.

Authors:  Sebastian Gurtner
Journal:  Eur J Health Econ       Date:  2011-11-05

6.  Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease.

Authors:  Paddy Gillespie; Eamon O'Shea; Andrew W Murphy; Susan M Smith; Mary C Byrne; Molly Byrne; Margaret E Cupples
Journal:  Eur J Health Econ       Date:  2011-05-03

7.  Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.

Authors:  George Gourzoulidis; Georgia Kourlaba; John Kakisis; Mitiadis Matsagkas; George Giannakoulas; Konstantinos I Gourgoulianis; Theodoros Vassilakopoulos; Nikos Maniadakis
Journal:  Clin Drug Investig       Date:  2017-09       Impact factor: 2.859

8.  Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam.

Authors:  Steven J Edwards; Sarah Wordsworth; Mike J Clarke
Journal:  Eur J Health Econ       Date:  2011-01-18

9.  A Monte Carlo Simulation to Estimate the Additional Cost Associated With Adverse Medication Events Leading to Intraoperative Hypotension and/or Hypertension in the United States.

Authors:  Karen C Nanji; Sofia D Shaikh; Alireza Jaffari; Calvin Franz; David W Bates
Journal:  J Patient Saf       Date:  2021-12-01       Impact factor: 2.844

10.  Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis.

Authors:  Mehdi Rezaee; Mohammad Hossein Morowvat; Maryam Poursadeghfard; Armin Radgoudarzi; Khosro Keshavarz
Journal:  BMC Health Serv Res       Date:  2022-01-28       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.